Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell free DNA test contingent on results from first trimester combined test
Cell free DNA (cfDNA) analysis of maternal blood for detection of trisomies 21, 18 and 13 is superior to other methods of screening but is expensive. One strategy to maximize performance at reduced cost is to offer cfDNA testing contingent on the results of the first trimester combined test that is used currently. The objectives of this study were to report the feasibility of implementing such screening, to examine the factors affecting patient decisions concerning their options for screening and decisions on the management of affected pregnancies and to report the prenatal diagnosis of fetal trisomies and outcome of affected pregnancies following the introduction of contingent screening.
Ultrasound in obstetrics gynecology the official journal of the International Society of Ultrasound in Obstetrics and Gynecology